Research ArticleInfectious Disease

TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci

See allHide authors and affiliations

Science Translational Medicine  09 Mar 2016:
Vol. 8, Issue 329, pp. 329ra32
DOI: 10.1126/scitranslmed.aad7364

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Addressing antibiotic resistance with nonantibiotic adjuvants

Coupled with the crisis in antibiotic drug resistance is a dearth of mechanistically new classes of antibacterial agents. One possible solution to this problem is to improve the efficacy of existing antibiotics against otherwise resistant bacteria using a combination agent approach. Lee et al. now describe just such a combination agent strategy to resuscitate the efficacy of β-lactam antibiotics. They identify nonantibiotic adjuvants termed tarocins that restore the killing activity of β-lactams against methicillin-resistant staphylococci, thereby enabling the application of β-lactams to treat Gram-positive bacterial infections.


The widespread emergence of methicillin-resistant Staphylococcus aureus (MRSA) has dramatically eroded the efficacy of current β-lactam antibiotics and created an urgent need for new treatment options. We report an S. aureus phenotypic screening strategy involving chemical suppression of the growth inhibitory consequences of depleting late-stage wall teichoic acid biosynthesis. This enabled us to identify early-stage pathway-specific inhibitors of wall teichoic acid biosynthesis predicted to be chemically synergistic with β-lactams. We demonstrated by genetic and biochemical means that each of the new chemical series discovered, herein named tarocin A and tarocin B, inhibited the first step in wall teichoic acid biosynthesis (TarO). Tarocins do not have intrinsic bioactivity but rather demonstrated potent bactericidal synergy in combination with broad-spectrum β-lactam antibiotics against diverse clinical isolates of methicillin-resistant staphylococci as well as robust efficacy in a murine infection model of MRSA. Tarocins and other inhibitors of wall teichoic acid biosynthesis may provide a rational strategy to develop Gram-positive bactericidal β-lactam combination agents active against methicillin-resistant staphylococci.

View Full Text

Stay Connected to Science Translational Medicine